Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System
ANN ARBOR, Mich., Jan. 27, 2012 /PRNewswire/ -- Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
Smartphone healthcare applications are graduating from novelty items to mainstream medicine, helping physicians to save lives and reduce the cost of care. Everist Genomics, a rapidly growing personalized medicine company, is successfully integrating smartphone and tablet computer technology with innovative, medically important diagnostics and prognostics in the areas of cardiovascular disease, metabolic disease (e.g. diabetes) and cancer. Everist Genomics' CardioDefender is the world's first FDA-approved and CE mark-registered smartphone ECG system to provide physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting. CardioDefender incorporates several unique capabilities enabling physicians to diagnose and treat potentially life-threatening heart arrhythmias that might otherwise be missed. CardioDefender is the first system to deliver mobile, real-time, beat-by-beat, and quantitative heart monitoring and automated reporting by combining patented analytical smartphone software with a Wi-Fi device and electrodes.
"The essence of personalized medicine is to diagnose a problem before there are noticeable symptoms. Physicians who diagnose and treat heart arrhythmias have been hampered for many years by legacy technology, such as hospital based ECG systems which confine patients to the high-cost hospital setting and Holter monitors which do not provide the comprehensi